Article
Radiology, Nuclear Medicine & Medical Imaging
Daniela-Elena Oprea-Lager, Eric Gontier, Lina Garcia-Canamaque, Mathieu Gauthe, Pierre Olivier, Mercedes Mitjavila, Pilar Tamayo, Philippe Robin, Ana Maria Garcia Vicente, Anne-Charlotte Bouyeure, Alban Bailliez, Antonio Rodriguez-Fernandez, Sinan Ben Mahmoud, Juan Antonio Vallejo-Casas, Philippe Maksud, Charles Merlin, Paul Blanc-Durand, Clement Drouet, Hubert Tissot, Irina Vierasu, Thierry Vander Borght, Evelyne Boos, Florence Chossat, Marina Hodolic, Caroline Rousseau
Summary: The purpose of this study was to compare the per-patient detection rates of [F-18]DCFPyL and [F-18]fluoromethylcholine PET/CT in patients with first prostate cancer biochemical recurrence. The results showed that [F-18]DCFPyL had a significantly higher detection rate compared to [F-18]fluoromethylcholine.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Elisa Perry, Arpit Talwar, Sanjana Sharma, Daisy O'Connor, Lih-Ming Wong, Kim Taubman, Tom R. Sutherland
Summary: This study retrospectively reviewed 1445 F-18-DCFPyL PSMA PET/CT studies and found that the detection of non-prostate cancer tumors (NPCaT) using PSMA imaging was low. In contrast, atypical prostate cancer metastases showed intermediate to high PSMA expression.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Esther Mena, Steven P. Rowe, Joanna H. Shih, Liza Lindenberg, Baris Turkbey, Aloyse Fourquet, Frank I. Lin, Stephen Adler, Philip Eclarinal, Yolanda L. McKinney, Deborah E. Citrin, William Dahut, Bradford J. Wood, Richard Chang, Elliot Levy, Maria Merino, Michael A. Gorin, Martin G. Pomper, Peter A. Pinto, Janet F. Eary, Peter L. Choyke, Kenneth J. Pienta
Summary: This study investigated the factors predicting scan positivity and disease location in patients with biochemical recurrence of prostate cancer after primary local therapy. PSA and PSAdt were found to be independent predictors of scan positivity and disease location.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ruohua Chen, Yining Wang, Yiping Shi, Yinjie Zhu, Lian Xu, Gang Huang, Jianjun Liu
Summary: Ga-68-PSMA PET/CT has a high detection rate in prostate cancer patients with biochemical recurrence, but few studies have explored other imaging methods for patients with negative Ga-68-PSMA findings. This study found that PSA level and Gleason score are independent predictors of F-18-FDG-positive findings, with patients with high PSA and Gleason score most likely to benefit from F-18-FDG PET/CT.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Keith L. Spinali, David J. Papke, Hina J. Shah
Summary: F-18-DCFPyl is used to detect recurrent or metastatic prostate cancer and can target nonprostatic disease entities that mimic prostate cancer. The interpreting physician needs to consider serum prostate-specific antigen levels and uptake distribution to avoid misdiagnosis of metastatic prostate cancer. We describe the association of F-18-DCFPyl uptake with a previously undescribed hepatic small vessel neoplasm.
CLINICAL NUCLEAR MEDICINE
(2023)
Editorial Material
Oncology
Lawrence D. True, Delphine L. Chen
Summary: Current imaging techniques for prostate cancer have limited sensitivity and specificity, but the novel PSMA agent F-18-DCFPyL-PET/CT shows promising performance.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Sara Harsini, Don Wilson, Heather Saprunoff, Hayley Allan, Martin Gleave, Larry Goldenberg, Kim N. Chi, Charmaine Kim-Sing, Scott Tyldesley, Francois Benard
Summary: This study examines the value of PSMA PET/CT-informed surgery and radiotherapy (RT) in patients with biochemical recurrence (BCR) treated without systemic therapy. The results suggest that RT or surgery based on PSMA PET/CT are associated with high PSA response rates. Further studies are needed to assess the impact of targeting these sites on patient relevant outcomes.
Article
Radiology, Nuclear Medicine & Medical Imaging
Dennie Meijer, Pim J. van Leeuwen, Pepijn M. J. Oosterholt, Yves J. L. Bodar, Henk G. van der Poel, N. Harry Hendrikse, Maarten L. Donswijk, Maurits Wondergem, Annelies E. Vellekoop, R. Jeroen A. van Moorselaar, Jakko A. Nieuwenhuijzen, Daniela E. Oprea-Lager, Andre N. Vis
Summary: This study aimed to investigate the impact of F-18-DCFPyL PET/CT on the intended management of patients with biochemically recurrent hormone-sensitive prostate cancer. Positive F-18-DCFPyL PET/CT scan, positive pathological lymph node status, and negative surgical margin status were significantly associated with an increased likelihood of a change in management based on F-18-DCFPyL PET/CT findings.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Review
Oncology
Ke-Hao Pan, Jin-Feng Wang, Chun-Ying Wang, Abdul Aziz Nikzad, Fang Q. Kong, Li Jian, Yin-Qiu Zhang, Xiao-Ming Lu, Bin Xu, Ya-Li Wang, Ming Chen
Summary: 18F-DCFPyL PSMA PET/CT has good sensitivity and specificity for diagnosing prostate cancer, with diagnostic rate correlated with PSA levels. Further large-scale, high-quality studies are needed in the future.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Ur Metser, Claudia Ortega, Douglas Hussey, Rosanna Chan, Alejandro Berlin, Antonio Finelli, Patrick Veit-Haibach
Summary: The initial experience of an academic center using F-18-DCFPyL PET in managing men with recurrent prostate cancer showed a high positivity rate (>90%) in patients with biochemical failure. PSMA PET-directed local ablative therapies resulted in a favorable outcome in more than 3 in 4 patients with limited recurrence, and nearly a quarter of them had a complete biochemical response.
Article
Oncology
Andrew F. Voter, Rudolf A. Werner, Kenneth J. Pienta, Michael A. Gorin, Martin G. Pomper, Lilja B. Solnes, Steven P. Rowe
Summary: This article provides an overview of PSMA, F-18-DCFPyL, and compares their performance to conventional prostate imaging modalities. The clinical trials OSPREY and CONDOR have shown the superiority of F-18-DCFPyL in staging and restaging prostate cancer. The remarkable diagnostic accuracy of PSMA-PET is reshaping prostate cancer imaging.
EXPERT REVIEW OF ANTICANCER THERAPY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Clemens Mingels, Karl Peter Bohn, Axel Rominger, Ali Afshar-Oromieh, Ian Alberts
Summary: This study investigated the diagnostic accuracy of [F-18]PSMA-1007 PET/CT in biochemically recurrent prostate cancer. The results showed good performance in terms of regional sensitivity and negative predictive value, but limited positive predictive value, especially for bone lesions.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Review
Oncology
Ali Sabbagh, Osama Mohamad, Katie E. Lichter, Thomas A. Hope
Summary: PSMA PET is increasingly used in the management of prostate cancer patients, improving accuracy in disease detection and changing clinical management. However, it is unclear whether this leads to improved patient survival or quality of life.
Article
Radiology, Nuclear Medicine & Medical Imaging
Maurits Wondergem, Friso M. van der Zant, Wouter A. M. Broos, Remco J. J. Knol
Summary: This study compared the performance of F-18-DCFPyL and F-18-PSMA-1007 in clinical imaging, revealing some significant differences between the two, particularly in the ability to detect prostate lesions in patients. These findings encourage further research and may have important implications for the selection of appropriate PSMA-targeting radiopharmaceuticals.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Elisa Perry, Arpit Talwar, Kim Taubman, Michael Ng, Lih-Ming Wong, Russell Booth, Tom R. Sutherland
Summary: This retrospective multicenter analysis evaluated the performance of PSMA PET/CT with [F-18]DCFPyL in detecting and localizing recurrent prostate cancer post RP. The study found that even at low PSA levels, the detection efficacy of [F-18]DCFPyL PET/CT was high, highlighting the importance of considering patients with PSA levels < 0.5 ng/mL in guidelines and funding pathways for PSMA PET/CT.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)